secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001641172-25-022153
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma: Phase 1 CDI-988 well tolerated; Phase 1b planned for norovirus
--------------------------------------------------------------------------------

- All CDI-988 doses (100-1200 mg) well tolerated in Phase 1 SAD and MAD cohorts; no severe AEs.
- Treatment-emergent AEs in SAD: 28% (10/36) CDI-988 vs 40% (4/10) placebo; MAD: 53% (19/36) vs 92% (11/12).
- Company expects to initiate Phase 1b challenge study in norovirus-infected healthy subjects later in 2025.
- Headache most common AE; no clinically relevant ECG changes or pathology results reported.
- CDI-988 targets 3CL viral proteases; potential prophylaxis/treatment for norovirus and coronaviruses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225022153/0001641172-25-022153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225022153/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-022153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer